Compare Mesoblast Limited (MESO) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Vanguard Short Term Corporate Bond ETF — how do they compare? Mesoblast Limited trades at $14.24 (market cap $1.75B), while Vanguard Short Term Corporate Bond ETF trades at $77.3 (market cap $51.90B). The key difference: Vanguard Short Term Corporate Bond ETF is far larger — about 29.7× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (239,027 versus 2,892,221). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Vanguard Short Term Corporate Bond ETF for 52 Days on average.
| MESO | VCSH | |
|---|---|---|
Market Cap | $1.75B | $51.90B |
Volume | 239,027 | 2,892,221 |
Sector | Health | Fixed Income |
52-Week High | $20.96 | $80.20 |
52-Week Low | $13.19 | $77.03 |
Typical Hold Time | 15 Days | 52 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
VCSH trades at $77.285 with minimal daily movement (+0.02%), showing technical bearish signals from moving averages while oscillators remain neutral. The ETF maintains a competitive 4.5% dividend yield with a low 0.03% expense ratio, though recent analysis suggests credit spreads appear tight. Recent institutional activity shows mixed positioning with both stake increases and reductions reported.
The short-term corporate bond ETF faces headwinds from potential rate environment shifts while offering higher yields than treasury alternatives. Limited price appreciation potential exists given current technical positioning and market expectations of sustained rates, making it suitable for income-focused investors comfortable with corporate credit risk exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
